The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. List of key ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...

MINNEAPOLIS -- The novel dual-function cardiac contractility modulation-defibrillator (CCM-D) for heart failure with reduced ejection fraction (HFrEF) had favorable early results in the Integra-D ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating ...

6MWD: 6-min walk distance; CARE-HF: Cardiac Resynchronization-Heart Failure; COMPANION: Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure; CRT-D: Cardiac resynchronization ...

Please provide your email address to receive an email when new articles are posted on . A novel implantable cardioverter defibrillator platform may benefit patients with HF not eligible for cardiac ...